Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.

Experimental study of intrathymic injection of donor spleen cells induces specific tolerance to cardiac allografts

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

[Induced Tolerance to Cardiac Allografts with Intrathymic Injection of Donor Spleen Cells].

Alteration Of Innate Immunity By Donor Il-6 Deficiency In A Presensitized Heart Transplant Model

[Induced Tolerance to Cardiac Allografts with Multiple Intravenous Injection of Donor Spleen Cells].

Donor IL-6 Deficiency Evidently Reduces Memory T Cell Responses in Sensitized Transplant Recipients.

Tolerance induction to cardiac allografts produced by neonatal intrathymic or intraperitoneal injection of donor spleen cells

Tolerance Induced by IL-6 Deficient Donor Heart is Significantly Involved in Myeloid-Derived Suppressor Cells (Mdscs).

Gut Microbes Enlarged the Protective Effect of Transplanted Regulatory B Cells on Rejection of Cardiac Allografts.

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

Cardiac Transplantation Tolerance Induced by Perioperative Injection of Spleen Cells Through Portal Vein in Allogeneic Rats

[Effect of T suppressor cells on the maintenance phase of tolerance to cardiac allografts in the rats].

Experimental study on immunotolerance induction to cardiac allografts in neonatal rat

Specific immunological tolerance induced by spleen transplantation in rats

Intrathymic Inoculation of Donor Liver Specific Antigen Alleviates Rejection of Liver Allotransplantation

Study on the Induction of Transplantation Tolerance in Mice by Continuous Infusion of Donor Spleen Cells and Its Mechanisms

The Relationship Between Th1/Th2 Cytokines Mrna Expression and Immune Tolerance to Cardiac Allografts in Rats

Combined Use of Vitamin D-derived Drug and DBMC to Induce Tolerance on Heterotopic Rat Cardiac Allograft

The Research of Oral Immune Tolerance and Skin Transplantation in Rats

Pretreatment of Donor Dendritic Cells with NBD-peptide Prolongs Mouse Cardiac Allograft Survival

Enhancement of Heart Transplantation Tolerance Induced with Cyclophosphamide by Infusion of Bone Marrow Cells in Rats